Page 42 Bain Capital Helthcare
P. 42
When Bain Capital first encountered what was then called
Quintiles Transnational, its core contract research (CRO)
business was clearly positioned for major growth. But
midway through the investment, Bain Capital helped the
company to also become a major provider of data to the
global pharmaceutical industry, and helped to propel the
pharmaceutical industry in the process.
Founded in 1982, by 2008 Quintiles had become the
leading global contract research organization, a provider
of outsourced clinical trials to the pharmaceutical industry.
It also had a smaller business providing outsourced
pharmaceutical sales teams.
The growth was driven in part by the tailwind of an industry
moving toward more variable cost structures but also by a
strong trend toward globalization of clinical development
programs. Quintiles had made significant investments
in its global footprint, which created significant strategic
differentiation. In addition, pharmaceuticals were being
transformed by the growing prominence of biotech
companies, which are heavier users of outsourced clinical
trial management than traditional large pharmaceutical
companies. Bain Capital had a vision of being a partner to
a company that was positioned better than any other to
benefit from these trends.
Quintiles’ founder, Dennis Gillings, and his original investor
group had begun to think about ways of growing beyond
the core CRO business. Impressed by Bain Capital’s strategic
Transforming Drug
Discovery
How IQVIA grew into the leading provider of contract
research and pharmaceutical data
IQVIA: Quick Facts
OVERVIEW
Leading provider of
biopharmaceutical development
services and pharmaceutical data
worldwide
HQ
Durham, NC
INVESTMENT
2008 (Quintiles)
KEY EVENTS
IPO (2013)
Merger with IMS (2016)
INVESTORS
Bain Capital Private Equity
Bain Capital Public Equity
WEBSITE
www.iqvia.com
42
Bain Capital
Healthcare
Quintiles Transnational, its core contract research (CRO)
business was clearly positioned for major growth. But
midway through the investment, Bain Capital helped the
company to also become a major provider of data to the
global pharmaceutical industry, and helped to propel the
pharmaceutical industry in the process.
Founded in 1982, by 2008 Quintiles had become the
leading global contract research organization, a provider
of outsourced clinical trials to the pharmaceutical industry.
It also had a smaller business providing outsourced
pharmaceutical sales teams.
The growth was driven in part by the tailwind of an industry
moving toward more variable cost structures but also by a
strong trend toward globalization of clinical development
programs. Quintiles had made significant investments
in its global footprint, which created significant strategic
differentiation. In addition, pharmaceuticals were being
transformed by the growing prominence of biotech
companies, which are heavier users of outsourced clinical
trial management than traditional large pharmaceutical
companies. Bain Capital had a vision of being a partner to
a company that was positioned better than any other to
benefit from these trends.
Quintiles’ founder, Dennis Gillings, and his original investor
group had begun to think about ways of growing beyond
the core CRO business. Impressed by Bain Capital’s strategic
Transforming Drug
Discovery
How IQVIA grew into the leading provider of contract
research and pharmaceutical data
IQVIA: Quick Facts
OVERVIEW
Leading provider of
biopharmaceutical development
services and pharmaceutical data
worldwide
HQ
Durham, NC
INVESTMENT
2008 (Quintiles)
KEY EVENTS
IPO (2013)
Merger with IMS (2016)
INVESTORS
Bain Capital Private Equity
Bain Capital Public Equity
WEBSITE
www.iqvia.com
42
Bain Capital
Healthcare
